{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:02:29Z","timestamp":1743134549911,"version":"3.40.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-025-01042-9","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T18:02:06Z","timestamp":1741802526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PBPK Modeling to Recommend Nevirapine Dosing in HIV and HIV-TB Co-infected Patients: Leveraging Enzyme Auto-Induction, Drug Interactions, and Ethnic Variability"],"prefix":"10.1208","volume":"27","author":[{"given":"Xuexin","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feiyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeneng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8427-4030","authenticated-orcid":false,"given":"Feifan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"issue":"4","key":"1042_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jama.300.4.423","volume":"300","author":"DV Havlir","year":"2008","unstructured":"Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA. 2008;300(4):423\u201330.","journal-title":"JAMA"},{"issue":"4","key":"1042_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/COH.0b013e32832c7d61","volume":"4","author":"SD Lawn","year":"2009","unstructured":"Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. Curr Opin HIV AIDS. 2009;4(4):325\u201333.","journal-title":"Curr Opin HIV AIDS"},{"key":"1042_CR3","unstructured":"WHO: Global Tuberculosis Report 2023. https:\/\/www.who.int\/publications\/m\/item\/top-findings-and-messages-gtb2023. Accessed 6 November 2023."},{"key":"1042_CR4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijid.2014.11.023","volume":"32","author":"QM Trinh","year":"2015","unstructured":"Trinh QM, Nguyen HL, Nguyen VN, Nguyen TV, Sintchenko V, Marais BJ. Tuberculosis and HIV co-infection-focus on the Asia-Pacific region. Int J Infect Dis. 2015;32:170\u20138.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"1042_CR5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/v16030321","volume":"16","author":"I Navasardyan","year":"2024","unstructured":"Navasardyan I, Miwalian R, Petrosyan A, Yeganyan S, Venketaraman V. HIV-TB Coinfection: Current Therapeutic Approaches and Drug Interactions. Viruses. 2024;16(3):321.","journal-title":"Viruses."},{"issue":"4","key":"1042_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1177\/135965350801300414","volume":"13","author":"A Avihingsanon","year":"2008","unstructured":"Avihingsanon A, Manosuthi W, Kantipong P, Chuchotaworn C, Moolphate S, Sakornjun W, et al. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther. 2008;13(4):529\u201336.","journal-title":"Antivir Ther"},{"issue":"9417","key":"1042_CR7","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","volume":"363","author":"F van Leth","year":"2004","unstructured":"van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363(9417):1253\u201363.","journal-title":"Lancet"},{"issue":"8","key":"1042_CR8","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0090-9556(24)15239-7","volume":"27","author":"P Riska","year":"1999","unstructured":"Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos. 1999;27(8):895\u2013901.","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"1042_CR9","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/S0090-9556(24)14960-4","volume":"27","author":"DA Erickson","year":"1999","unstructured":"Erickson DA, Mather G, Trager WF, Levy RH, Keirns JJ. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos. 1999;27(12):1488\u201395.","journal-title":"Drug Metab Dispos"},{"key":"1042_CR10","doi-asserted-by":"crossref","unstructured":"Gopalan BP, Mehta K, D'Souza R R, Rajnala N, A KH, Ramachandran G, et al. Sub-therapeutic nevirapine concentration during antiretroviral treatment initiation among children living with HIV: Implications for therapeutic drug monitoring. PLoS One. 2017;12(8):e0183080.","DOI":"10.1371\/journal.pone.0183080"},{"issue":"2","key":"1042_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0009-9236(99)80079-4","volume":"65","author":"M Lamson","year":"1999","unstructured":"Lamson M, MacGregor T, Riska P, Erickson D, Maxfield P, Rowland L, et al. Nevirapine Induces Both CYP3A4 and CYP2B6 Metabolic Pathways. Clin Pharmacol Ther. 1999;65(2):137.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1042_CR12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0022-3565(24)29202-8","volume":"299","author":"JM Rae","year":"2001","unstructured":"Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther. 2001;299(3):849\u201357.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1042_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1164\/ajrccm.164.1.2101133","volume":"164","author":"WJ Burman","year":"2001","unstructured":"Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med. 2001;164(1):7\u201312.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1042_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00228-008-0481-y","volume":"65","author":"D Elsherbiny","year":"2009","unstructured":"Elsherbiny D, Cohen K, Jansson B, Smith P, McIlleron H, Simonsson US. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. Eur J Clin Pharmacol. 2009;65(1):71\u201380.","journal-title":"Eur J Clin Pharmacol"},{"key":"1042_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ejps.2017.05.043","volume":"106","author":"O Olafuyi","year":"2017","unstructured":"Olafuyi O, Coleman M, Badhan RKS. Development of a paediatric physiologically based pharmacokinetic model to assess the impact of drug-drug interactions in tuberculosis co-infected malaria subjects: A case study with artemether-lumefantrine and the CYP3A4-inducer rifampicin. Eur J Pharm Sci. 2017;106:20\u201333.","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"1042_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00228-001-0396-3","volume":"57","author":"X Wen","year":"2002","unstructured":"Wen X, Wang JS, Neuvonen PJ, Backman JT. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur J Clin Pharmacol. 2002;57(11):799\u2013804.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1042_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00228-004-0769-5","volume":"60","author":"E Dailly","year":"2004","unstructured":"Dailly E, Billaud E, Reliquet V, Breurec S, Perr\u00e9 P, L\u00e9autez S, et al. No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors. Eur J Clin Pharmacol. 2004;60(5):343\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1042_CR18","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1046\/j.1365-2125.2002.01657.x","volume":"54","author":"MM de Maat","year":"2002","unstructured":"de Maat MM, Huitema AD, Mulder JW, Meenhorst PL, van Gorp EC, Beijnen JH. Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol. 2002;54(4):378\u201385.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1042_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/135965350501000114","volume":"10","author":"BS Kappelhoff","year":"2005","unstructured":"Kappelhoff BS, van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther. 2005;10(1):145\u201355.","journal-title":"Antivir Ther"},{"issue":"7","key":"1042_CR20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3851\/IMP2741","volume":"19","author":"T Wattanakul","year":"2014","unstructured":"Wattanakul T, Avihingsanon A, Manosuthi W, Punyawudho B. Population pharmacokinetics of nevirapine in Thai HIV-infected patients. Antivir Ther. 2014;19(7):651\u201360.","journal-title":"Antivir Ther"},{"issue":"13","key":"1042_CR21","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2165\/00003088-200443130-00002","volume":"43","author":"BS Kappelhoff","year":"2004","unstructured":"Kappelhoff BS, Crommentuyn KM, de Maat MM, Mulder JW, Huitema AD, Beijnen JH. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet. 2004;43(13):845\u201353.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1042_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/01.qai.0000214808.75594.73","volume":"42","author":"G Ramachandran","year":"2006","unstructured":"Ramachandran G, Hemanthkumar AK, Rajasekaran S, Padmapriyadarsini C, Narendran G, Sukumar B, et al. Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. J Acquir Immune Defic Syndr. 2006;42(1):36\u201341.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"1042_CR23","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1177\/135965350501000809","volume":"10","author":"RS Autar","year":"2005","unstructured":"Autar RS, Wit FW, Sankote J, Mahanontharit A, Anekthananon T, Mootsikapun P, et al. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. Antivir Ther. 2005;10(8):937\u201343.","journal-title":"Antivir Ther"},{"issue":"2","key":"1042_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/jac\/dkm484","volume":"61","author":"K Cohen","year":"2008","unstructured":"Cohen K, van Cutsem G, Boulle A, McIlleron H, Goemaere E, Smith PJ, et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother. 2008;61(2):389\u201393.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"1042_CR25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2165\/00003088-200342060-00009","volume":"42","author":"TE de Vries-Sluijs","year":"2003","unstructured":"de Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, Schutten M, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet. 2003;42(6):599\u2013605.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1042_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1517\/17425250903393752","volume":"6","author":"A Kwara","year":"2010","unstructured":"Kwara A, Ramachandran G, Swaminathan S. Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert Opin Drug Metab Toxicol. 2010;6(1):55\u201368.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"1042_CR27","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.1208\/ps060106","volume":"6","author":"M Rowland","year":"2004","unstructured":"Rowland M, Balant L, Peck C. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29\u201330, 2002). AAPS PharmSci. 2004;6(1):E6.","journal-title":"AAPS PharmSci"},{"issue":"4","key":"1042_CR28","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1097\/QAI.0b013e3181e2d5e5","volume":"54","author":"YS Cramer","year":"2010","unstructured":"Cramer YS, Rosenkranz SL, Hall SD, Szczech LA, Amorosa V, Gupta SK. Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177. J Acquir Immune Defic Syndr. 2010;54(4):e7-9.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"1042_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40262-016-0457-5","volume":"56","author":"MM De Sousa","year":"2017","unstructured":"De Sousa MM, Lui G, Zheng Y, Pressiat C, Hirt D, Valade E, et al. A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways. Clin Pharmacokinet. 2017;56(5):537\u201350.","journal-title":"Clin Pharmacokinet"},{"issue":"13","key":"1042_CR30","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/S0149-2918(10)80028-1","volume":"32","author":"Y Zhu","year":"2010","unstructured":"Zhu Y, Zhang Q, Yu C, Zou J, Yang X, Hu Y. Relative bioavailability of two formulations of nevirapine 200-mg tablets in healthy Chinese male volunteers: A single-dose, randomized-sequence, open-label, two-way crossover study. Clin Ther. 2010;32(13):2258\u201364.","journal-title":"Clin Ther"},{"issue":"6","key":"1042_CR31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/(SICI)1099-081X(199909)20:6<285::AID-BDD187>3.0.CO;2-V","volume":"20","author":"MJ Lamson","year":"1999","unstructured":"Lamson MJ, Sabo JP, MacGregor TR, Pav JW, Rowland L, Hawi A, et al. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Dispos. 1999;20(6):285\u201391.","journal-title":"Biopharm Drug Dispos"},{"issue":"8","key":"1042_CR32","doi-asserted-by":"publisher","first-page":"F77","DOI":"10.1097\/00002030-200005260-00001","volume":"14","author":"RP van Heeswijk","year":"2000","unstructured":"van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS. 2000;14(8):F77-82.","journal-title":"AIDS"},{"issue":"1","key":"1042_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1124\/jpet.106.112136","volume":"320","author":"SR Faucette","year":"2007","unstructured":"Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther. 2007;320(1):72\u201380.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"1042_CR34","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1111\/cts.13614","volume":"16","author":"OU Amaeze","year":"2023","unstructured":"Amaeze OU, Isoherranen N. Application of a physiologically based pharmacokinetic model to predict isoniazid disposition during pregnancy. Clin Transl Sci. 2023;16(11):2163\u201376.","journal-title":"Clin Transl Sci"},{"issue":"10","key":"1042_CR35","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00228-007-0333-1","volume":"63","author":"R Kubota","year":"2007","unstructured":"Kubota R, Ohno M, Hasunuma T, Iijima H, Azuma J. Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2. Eur J Clin Pharmacol. 2007;63(10):927\u201333.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"1042_CR36","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/QAI.0b013e3181b0328f","volume":"52","author":"A Matteelli","year":"2009","unstructured":"Matteelli A, Saleri N, Villani P, Bonkoungou V, Carvalho AC, Kouanda S, et al. Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. J Acquir Immune Defic Syndr. 2009;52(1):64\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"1042_CR37","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/00042560-200112150-00007","volume":"28","author":"E Ribera","year":"2001","unstructured":"Ribera E, Pou L, Lopez RM, Crespo M, Falco V, Oca\u00f1a I, et al. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. J Acquir Immune Defic Syndr. 2001;28(5):450\u20133.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"1042_CR38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/psp4.12088","volume":"5","author":"A Ke","year":"2016","unstructured":"Ke A, Barter Z, Rowland-Yeo K, Almond L. Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6. CPT Pharmacometrics Syst Pharmacol. 2016;5(7):367\u201376.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"1042_CR39","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/14740338.2020.1694901","volume":"19","author":"M Cerrone","year":"2020","unstructured":"Cerrone M, Bracchi M, Wasserman S, Pozniak A, Meintjes G, Cohen K, et al. Safety implications of combined antiretroviral and anti-tuberculosis drugs. Expert Opin Drug Saf. 2020;19(1):23\u201341.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"1042_CR40","first-page":"197","volume":"14","author":"M Moses","year":"2010","unstructured":"Moses M, Zachariah R, Tayler-Smith K, Misinde D, Foncha C, Manzi M, et al. Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi. Int J Tuberc Lung Dis. 2010;14(2):197\u2013202.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1042_CR41","unstructured":"Nafrialdi, Nugroho AW, Yunihastuti E, Wiria MS. Influence of rifampicin on nevirapine plasma concentration in HIV-TB coinfected patients. Acta Med Indones. 2012;44(2):135\u20139."},{"issue":"4","key":"1042_CR42","doi-asserted-by":"publisher","first-page":"e94854","DOI":"10.1371\/journal.pone.0094854","volume":"9","author":"FS Sarfo","year":"2014","unstructured":"Sarfo FS, Sarfo MA, Norman B, Phillips R, Chadwick D. Incidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine\u2019s epitaph? PLoS ONE. 2014;9(4):e94854.","journal-title":"PLoS ONE"},{"issue":"12","key":"1042_CR43","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1097\/QAD.0b013e3282170a9d","volume":"21","author":"E Phillips","year":"2007","unstructured":"Phillips E, Guti\u00e9rrez S, Jahnke N, Yip B, Lima VD, Hogg RS, et al. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients. AIDS. 2007;21(12):1561\u20138.","journal-title":"AIDS"},{"issue":"6","key":"1042_CR44","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1086\/528861","volume":"46","author":"FW Wit","year":"2008","unstructured":"Wit FW, Kesselring AM, Gras L, Richter C, van der Ende ME, Brinkman K, et al. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study. Clin Infect Dis. 2008;46(6):933\u201340.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"1042_CR45","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/00002030-200501280-00011","volume":"19","author":"J Ananworanich","year":"2005","unstructured":"Ananworanich J, Moor Z, Siangphoe U, Chan J, Cardiello P, Duncombe C, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS. 2005;19(2):185\u201392.","journal-title":"AIDS"},{"issue":"2","key":"1042_CR46","first-page":"141","volume":"40","author":"M Hasan","year":"2022","unstructured":"Hasan M, Yunihastuti E, Teguh HK, Abdullah M. Incidence and predictors of nevirapine and efavirenz-associated rash among Indonesian HIV patients. Asian Pac J Allergy Immunol. 2022;40(2):141\u20136.","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"15","key":"1042_CR47","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1097\/00002030-199815000-00026","volume":"12","author":"TT Ho","year":"1998","unstructured":"Ho TT, Wong KH, Chan KC, Lee SS. High incidence of nevirapine-associated rash in HIV-infected Chinese. AIDS. 1998;12(15):2082\u20133.","journal-title":"AIDS"},{"issue":"15","key":"1042_CR48","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1097\/00002030-200310170-00019","volume":"17","author":"N Kumarasamy","year":"2003","unstructured":"Kumarasamy N, Solomon S, Chaguturu SK, Mahajan AP, Flanigan TP, Balakrishnan P, et al. The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India. AIDS. 2003;17(15):2267\u20139.","journal-title":"AIDS"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01042-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-025-01042-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-025-01042-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T03:23:56Z","timestamp":1743045836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-025-01042-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":48,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["1042"],"URL":"https:\/\/doi.org\/10.1208\/s12248-025-01042-9","relation":{},"ISSN":["1550-7416"],"issn-type":[{"type":"electronic","value":"1550-7416"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"19 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declared no conflict of interest for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"59"}}